2,3,7,8‑Tetrachlorodibenzo‑p‑dioxin suppresses the growth of human liver cancer HepG2 cells in vitro: Involvement of cell signaling factors

Yamaguchi,Masayoshi; Hankinson,Oliver

doi:10.3892/ijo.2018.4507

2,3,7,8‑Tetrachlorodibenzo‑p‑dioxin suppresses the growth of human liver cancer HepG2 cells in vitro: Involvement of cell signaling factors

Authors:
- Masayoshi Yamaguchi
- Oliver Hankinson
View Affiliations

Affiliations: Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095‑1723, USA
Published online on: July 27, 2018 https://doi.org/10.3892/ijo.2018.4507
Pages: 1657-1666

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aryl hydrocarbon receptor (AHR) is transcriptionally active in the form of a heterodimer with the AHR nuclear translocator, which then binds to the xenobiotic responsive element. AHR was originally discovered via its ligand, the polychlorinated hydrocarbon, 2,3,7,8‑tetrachlorodibenzo‑p‑dioxin (TCDD). In this study, we investigated whether TCDD regulates the growth of human liver cancer HepG2 cells in vitro. TCDD (0.1‑100 nM) was found to exert suppressive effects on the colony formation and proliferation of HepG2 cells, and stimulatory effects on the death of HepG2 cells when the cells reached subconfluence. The effects of TCDD on the HepG2 cells were abolished by culture with CH223191, an inhibitor of AHR signaling. The effects of TCDD were dependent on the concentration of serum, which contains various signaling factors. The effects of TCDD were not potentiated by culture with tumor necrosis factor‑α, which activates the signaling of nuclear factor‑κB (NF‑κB). The results of western blot analysis revealed that TCDD increased the protein levels of p53, Rb, p21, and regucalcin, which are suppressors of the growth of tumor cells. Moreover, TCDD enhanced the NF‑κB p65, β‑catenin, signal transducer and activator of transcription 3 (STAT3), Ras and Akt levels. Thus, the findings of this study indicate that TCDD may suppress liver cancer cell growth through various signaling pathways, mediated by AHR and its‑related co‑factors. Of note, the effects of TCDD were found to be potentiated by gemcitabine, which induces nuclear DNA damage in cancer cells, suggesting that their combined use may have potential as a suppressor of tumor cell growth.

View Figures

View References

1	Hankinson O: The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol. 35:307–340. 1995. View Article : Google Scholar : PubMed/NCBI
2	Hankinson O: Role of coactivators in transcriptional activation by the aryl hydrocarbon receptor. Arch Biochem Biophys. 433:379–386. 2005. View Article : Google Scholar
3	Kamenickova A, Anzenbacherova E, Pavek P, Soshilov AA, Denison MS, Anzenbacher P and Dvorak Z: Pelargonidin activates the AhR and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T. Toxicol Lett. 218:253–259. 2013. View Article : Google Scholar : PubMed/NCBI
4	Kamenickova A, Anzenbacherova E, Pavek P, Soshilov AA, Denison MS, Zapletalova M, Anzenbacher P and Dvorak Z: Effects of anthocyanins on the AhR-CYP1A1 signaling pathway in human hepatocytes and human cancer cell lines. Toxicol Lett. 221:1–8. 2013. View Article : Google Scholar : PubMed/NCBI
5	Dvorak Z, Vrzal R, Henklova P, Jancova P, Anzenbacherova E, Maurel P, Svecova L, Pavek P, Ehrmann J, Havlik R, et al: JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes. Biochem Pharmacol. 75:580–588. 2008. View Article : Google Scholar
6	Pastorková B, Vrzalová A, Bachleda P and Dvořák Z: Hydroxystilbenes and methoxystilbenes activate human aryl hydrocarbon receptor and induce CYP1A genes in human hepatoma cells and human hepatocytes. Food Chem Toxicol. 103:122–132. 2017. View Article : Google Scholar : PubMed/NCBI
7	Palermo CM, Hernando JI, Dertinger SD, Kende AS and Gasiewicz TA: Identification of potential aryl hydrocarbon receptor antagonists in green tea. Chem Res Toxicol. 16:865–872. 2003. View Article : Google Scholar : PubMed/NCBI
8	Go RE, Hwang KA and Choi KC: Cytochrome P450 1 family and cancers. J Steroid Biochem Mol Biol. 147:24–30. 2015. View Article : Google Scholar
9	Stejskalova L and Pavek P: The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor (AhR) in the placenta. Curr Pharm Biotechnol. 12:715–730. 2011. View Article : Google Scholar : PubMed/NCBI
10	Forrester AR, Elias MS, Woodward EL, Graham M, Williams FM and Reynolds NJ: Induction of a chloracne phenotype in an epidermal equivalent model by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is dependent on aryl hydrocarbon receptor activation and is not reproduced by aryl hydrocarbon receptor knock down. J Dermatol Sci. 73:10–22. 2014. View Article : Google Scholar :
11	Pierre S, Chevallier A, Teixeira-Clerc F, Ambolet-Camoit A, Bui LC, Bats AS, Fournet JC, Fernandez-Salguero P, Aggerbeck M, Lotersztajn S, et al: Aryl hydrocarbon receptor-dependent induction of liver fibrosis by dioxin. Toxicol Sci. 137:114–124. 2014. View Article : Google Scholar
12	Wu D, Nishimura N, Kuo V, Fiehn O, Shahbaz S, Van Winkle L, Matsumura F and Vogel CF: Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E^−/− mice. Arterioscler Thromb Vasc Biol. 31:1260–1267. 2011. View Article : Google Scholar : PubMed/NCBI
13	Roh E, Kwak SH, Jung HS, Cho YM, Pak YK, Park KS, Kim SY and Lee HK: Serum aryl hydrocarbon receptor ligand activity is associated with insulin resistance and resulting type 2 diabetes. Acta Diabetol. 52:489–495. 2015. View Article : Google Scholar
14	Brito JS, Borges NA, Esgalhado M, Magliano DC, Soulage CO and Mafra D: Aryl hydrocarbon receptor activation in chronic kidney disease: Role of uremic toxins. Nephron. 137:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
15	Esser C: The aryl hydrocarbon receptor in immunity: Tools and potential. Methods Mol Biol. 1371:239–257. 2016. View Article : Google Scholar
16	Murray IA, Patterson AD and Perdew GH: Aryl hydrocarbon receptor ligands in cancer: Friend and foe. Nat Rev Cancer. 14:801–814. 2014. View Article : Google Scholar
17	Nukaya M, Moran S and Bradfield CA: The role of the dioxin-responsive element cluster between the Cyp1a1 and Cyp1a2 loci in aryl hydrocarbon receptor biology. Proc Natl Acad Sci USA. 106:4923–4928. 2009. View Article : Google Scholar : PubMed/NCBI
18	Uno S, Dalton TP, Sinclair PR, Gorman N, Wang B, Smith AG, Miller MI, Shertzer HG and Nebert DW: Cyp1a1(−/−) male mice: Protection against high-dose TCDD-induced lethality and wasting syndrome, and resistance to intrahepatocyte lipid accumulation and uroporphyria. Toxicol Appl Pharmacol. 196:410–421. 2004. View Article : Google Scholar : PubMed/NCBI
19	Singh KP, Garrett RW, Casado FL and Gasiewicz TA: Aryl hydrocarbon receptor-null allele mice have hematopoietic stem/progenitor cells with abnormal characteristics and functions. Stem Cells Dev. 20:769–784. 2011. View Article : Google Scholar :
20	Barouki R, Coumoul X and Fernandez-Salguero PM: The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett. 581:3608–3615. 2007. View Article : Google Scholar : PubMed/NCBI
21	Mulero-Navarro S and Fernandez-Salguero PM: New trends in aryl hydrocarbon receptor biology. Front Cell Dev Biol. 4:452016. View Article : Google Scholar : PubMed/NCBI
22	Moennikes O, Loeppen S, Buchmann A, Andersson P, Ittrich C, Poellinger L and Schwarz M: A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 64:4707–4710. 2004. View Article : Google Scholar : PubMed/NCBI
23	Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y and Puga A: The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res. 70:212–220. 2010. View Article : Google Scholar
24	Corchero J, Martín-Partido G, Dallas SL and Fernández-Salguero PM: Liver portal fibrosis in dioxin receptor-null mice that overexpress the latent transforming growth factor-beta-binding protein-1. Int J Exp Pathol. 85:295–302. 2004. View Article : Google Scholar : PubMed/NCBI
25	Schmidt JV, Su GH-T, Reddy JK, Simon MC and Bradfield CA: Characterization of a murine Ahr null allele: Involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci USA. 93:6731–6736. 1996. View Article : Google Scholar : PubMed/NCBI
26	Lahvis GP, Lindell SL, Thomas RS, McCuskey RS, Murphy C, Glover E, Bentz M, Southard J and Bradfield CA: Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. Proc Natl Acad Sci USA. 97:10442–10447. 2000. View Article : Google Scholar : PubMed/NCBI
27	Jackson DP, Li H, Mitchell KA, Joshi AD and Elferink CJ: Ah receptor-mediated suppression of liver regeneration through NC-XRE-driven p21Cip1 expression. Mol Pharmacol. 85:533–541. 2014. View Article : Google Scholar : PubMed/NCBI
28	Mathew LK, Simonich MT and Tanguay RL: AHR-dependent misregulation of Wnt signaling disrupts tissue regeneration. Biochem Pharmacol. 77:498–507. 2009. View Article : Google Scholar :
29	Moreno-Marín N, Barrasa E, Morales-Hernández A, Paniagua B, Blanco-Fernández G, Merino JM and Fernández-Salguero PM: Dioxin receptor adjust liver regeneration after acute toxic injury and protects against liver carcinogenesis. Sci Rep. 7:104202017. View Article : Google Scholar
30	Knowles BB, Howe CC and Aden DP: Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 209:497–499. 1980. View Article : Google Scholar : PubMed/NCBI
31	Choi EY, Lee H, Dingle RWC, Kim KB and Swanson HI: Development of novel CH223191-based antagonists of the aryl hydrocarbon receptor. Mol Pharmacol. 81:3–11. 2012. View Article : Google Scholar :
32	Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, Guo X, Wang W, Jiao W, Xu Z and Liu Z: See comment in PubMed Commons belowSimvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS One. 8:e628232013. View Article : Google Scholar
33	Wang K, Li Y, Jiang YZ, Dai CF, Patankar MS, Song JS and Zheng J: An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells. Cancer Lett. 340:63–71. 2013. View Article : Google Scholar : PubMed/NCBI
34	Yamaguchi M and Daimon Y: Overexpression of regucalcin suppresses cell proliferation in cloned rat hepatoma H4-II-E cells: Involvement of intracellular signaling factors and cell cycle-related genes. J Cell Biochem. 95:1169–1177. 2005. View Article : Google Scholar : PubMed/NCBI
35	Izumi T and Yamaguchi M: Overexpression of regucalcin suppresses cell death in cloned rat hepatoma H4-II-E cells induced by tumor necrosis factor-alpha or thapsigargin. J Cell Biochem. 92:296–306. 2004. View Article : Google Scholar : PubMed/NCBI
36	Yamaguchi M, Osuka S, Weitzmann MN, El-Rayes BF, Shoji M and Murata T: Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro. Int J Oncol. 48:1955–1964. 2016. View Article : Google Scholar : PubMed/NCBI
37	Yamaguchi M and Isogai M: Tissue concentration of calcium-binding protein regucalcin in rats by enzyme-linked immunoadsorbent assay. Mol Cell Biochem. 122:65–68. 1993. View Article : Google Scholar : PubMed/NCBI
38	Vaziri C, Schneider A, Sherr DH and Faller DV: Expression of AHR is regulated by serum and mitogenic growth factors in murine 3T3 fibroblasts. J Biol Chem. 271:25921–25927. 1996. View Article : Google Scholar : PubMed/NCBI
39	Umannová L, Zatloukalová J, Machala M, Krcmár P, Májková Z, Hennig B, Kozubík A and Vondrácek J: Tumor necrosis factor-α modulates effects of aryl hydrocarbon receptor ligands on cell proliferation and expression of cytochrome P450 enzymes in rat liver 'stem-like' cells. Toxicol Sci. 99:79–89. 2007. View Article : Google Scholar
40	Tsurusaki Y and Yamaguchi M: Role of regucalcin in liver nuclear function: Binding of regucalcin to nuclear protein or DNA and modulation of tumor-related gene expression. Int J Mol Med. 14:277–281. 2004.PubMed/NCBI
41	Yamaguchi M: Suppressive role of regucalcin in liver cell proliferation: Involvement in carcinogenesis. Cell Prolif. 46:243–253. 2013. View Article : Google Scholar : PubMed/NCBI
42	Tang SC and Chen YC: Novel therapeutic targets for pancreatic cancer. World J Gastroenterol. 20:10825–10844. 2014. View Article : Google Scholar : PubMed/NCBI
43	Vogel CFA, Wu D, Goth SR, Baek J, Lollies A, Domhardt R, Grindel A and Pessah IN: Aryl hydrocarbon receptor signaling regulates NF-κB RelB activation during dendritic-cell differentiation. Immunol Cell Biol. 91:568–575. 2013. View Article : Google Scholar : PubMed/NCBI
44	Han M, Liu X, Liu S, Su G, Fan X, Chen J, Yuan Q and Xu G: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces hepatic stellate cell (HSC) activation and liver fibrosis in C57BL6 mouse via activating Akt and NF-κB signaling pathways. Toxicol Lett. 273:10–19. 2017. View Article : Google Scholar : PubMed/NCBI
45	Jennen D, Ruiz-Aracama A, Magkoufopoulou C, Peijnenburg A, Lommen A, van Delft J and Kleinjans J: Integrating transcriptomics and metabonomics to unravel modes-of-action of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in HepG2 cells. BMC Syst Biol. 5:1392011. View Article : Google Scholar : PubMed/NCBI
46	Nejak-Bowen KN, Zeng G, Tan X, Cieply B and Monga SP: Beta-catenin regulates vitamin C biosynthesis and cell survival in murine liver. J Biol Chem. 284:28115–28127. 2009. View Article : Google Scholar : PubMed/NCBI
47	Yamaguchi M, Osuka S, Weitzmann MN, El-Rayes BF, Shoji M and Murata T: Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitro. Int J Oncol. 49:1686–1694. 2016. View Article : Google Scholar : PubMed/NCBI